Another paper imploring doctors NOT to order T3 tests.
Their reason is claimed to be: may reduce inappropriate monitoring practices, decrease costs, and improve utilization of limited healthcare resources
Given that the biggest burdens of doing blood tests is probably on the doctor ordering, the phlebotomist doing the blood draw, the lab interacting with the blood sample and returning results, and any follow-up, the marginal cost (or burden) of doing T3 at the same time as TSH (or, for that matter, many other blood tests) is probably a vanishingly small amount.
The inappropriateness for an individual can only be judged after the test. Otherwise, it is simply an assumption that a T3 test would add nothing and hence be inappropriate.
I'd also point out that as written, it would also declare block and replace patients as inappropriate for T3 tests. It does say the alert appears when the patient is on levothyroxine without regard as to why.
When a test is newly developed, it is claimed to do wonderful things. What happened between then and now which makes it such an awful test to order?
Note the prejudging implicit in the title. They KNOW which tests would be inappropriate without even knowing the patient exists.
Endocr Pract. 2019 Aug 14. doi: 10.4158/EP-2019-0215. [Epub ahead of print]
REDUCING INAPPROPRIATE SERUM T3 LABORATORY TEST ORDERING IN PATIENTS WITH TREATED HYPOTHYROIDISM.
Sue LY1, Kim JE2, Oza H3, Chong T4, Woo HE5, Cheng EM6, Leung AM1.
Author information
1 From: 1Division of Endocrinology, Diabetes & Metabolism; Department of Medicine; University of California Los Angeles (UCLA) David Geffen School of Medicine and VA Greater Los Angeles Healthcare System.
2 Division of Endocrinology and Metabolism, University of California San Francisco School of Medicine.
3 UCLA Health Information Technology.
4 Department of Pathology, UCLA David Geffen School of Medicine.
5 Department of Medicine, UCLA David Geffen School of Medicine.
6 Department of Neurology, UCLA David Geffen School of Medicine.
Abstract
Objective: Choosing Wisely is a campaign of the American Board of Internal Medicine that aims to promote evidence-based practices to reduce unnecessary ordering of tests or procedures. As part of this campaign, the Endocrine Society advises against ordering a serum total or free triiodothyronine (T3) level when assessing levothyroxine dosing in hypothyroid patients. This study was performed to assess and reduce inappropriate laboratory ordering practices among providers who manage patients with hypothyroidism within a large U.S. academic health system. Methods: A best practice alert (BPA) in the health record was developed and implemented following the collection of baseline data. This alert consisted of a pop-up window that was triggered when a serum T3 laboratory test was ordered for patients prescribed levothyroxine. The alert required user acknowledgement before the serum T3 laboratory test could be ordered. Results: During the six-week period prior to launching the BPA, serum T3 tests were ordered a mean of 162.3 ± 15.4 [standard deviation] occurrences per 10,000 patients per week. Over a 15-week period following implementation of the BPA, the frequency of serum T3 orders steadily decreased and resulted in >44% fewer inappropriate tests being ordered. Conclusion: Although national societal guidelines recommend against ordering serum T3 concentrations while monitoring patients with hypothyroidism managed with levothyroxine, these laboratory tests are frequently ordered. Development of a triggered alert in the health record may reduce inappropriate monitoring practices, decrease costs, and improve utilization of limited healthcare resources for this common clinical condition. Abbreviations T3 = triiodothyronine; BPA = best practice alert; ATA = American Thyroid Association; U.S. = United States; TSH = thyroid stimulating hormone.
KEYWORDS:
hypothyroidism; thyroid diseases; thyroid dysfunction
PMID: 31412225
DOI: 10.4158/EP-2019-0215